Raymond James Maintains Outperform on Myriad Genetics, Raises Price Target to $27
Raymond James analyst Andrew Cooper maintains Myriad Genetics (NASDAQ:MYGN) with a Outperform and raises the price target from $25 to $27.
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session.
Insiders Selling DocuSign, Adobe And 2 Other Stocks
The Nasdaq settled higher by 2% on Monday. Investors, meanwhile, focused on some notable insider trades.
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock
Raymond James upgraded Natera Inc (NASDAQ:NTRA) to Outperform from Market Perform and a price target of $58 on a catalyst-rich setup for 2023…
Raymond James Upgrades Myriad Genetics to Outperform, Announces $25 Price Target
Raymond James analyst Andrew Cooper upgrades Myriad Genetics (NASDAQ:MYGN) from Market Perform to Outperform and announces $25 price target.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 325 companies set new 52-week lows.
Reported Late Thursday, Myriad Genetics Patient Outcomes Study Shows RiskScore Leads To More Accurate Breast Cancer Risk Prediction Than Standard-Of-Care Risk Model
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today presented results from a longitudinal study validating RiskScore as a well-calibrated and more accurate predictor
SVB Leerink Maintains Market Perform on Myriad Genetics, Lowers Price Target to $25
SVB Leerink analyst Puneet Souda maintains Myriad Genetics (NASDAQ:MYGN) with a Market Perform and lowers the price target from $27 to $25.